每日一次单吸入器三联疗法(FF/UMEC/VI)与FF/VI在控制不佳哮喘患者中的疗效与安全性(CAPTAIN):一项双盲、随机、3A期试验
CAPTAIN研究为双盲、随机、平行组3A期试验,纳入416家医院和初级保健中心、15个国家的2439例≥18岁、ICS/LABA控制不佳(ACQ-6≥1.5)、FEV1占预计值30%至<85%且支气管舒张试验阳性的哮喘患者,随机接受每日一次FF/VI(100/25 μg或200/25 μg)或FF/UMEC/VI(100/31.25/25 μg、100/62.5/25 μg、200/31.25/25 μg、200/62.5/25 μg)。第24周谷FEV1较基线改善:FF/UMEC/VI 100/62.5/25 μg vs FF/VI 100/25 μg为110 mL(95%CI 66-153;p<0.0001),200/62.5/25 μg vs 200/25 μg为92 mL(49-135;p<0.0001);加用UMEC 31.25 μg亦改善(96 mL [52-139;p<0.0001];82 mL [39-125;p=0.0002])。中重度急性发作率降低未达统计学显著。作者认为单吸入器FF/UMEC/VI是有效治疗选择,高剂量FF主要降低急性发作率,尤其在2型炎症生物标志物升高患者中。
要点
- ICS/LABA控制不佳的中重度哮喘患者,加用UMEC后第24周谷FEV1较FF/VI改善:100/62.5/25 μg组110 mL(95%CI 66-153),200/62.5/25 μg组92 mL(49-135),均p<0.0001。
- 加用UMEC 31.25 μg亦改善谷FEV1:100/31.25/25 μg vs 100/25 μg为96 mL(52-139;p<0.0001),200/31.25/25 μg vs 200/25 μg为82 mL(39-125;p=0.0002)。
- 中重度急性发作率降低未达统计学显著;FF 200 μg组急性发作率低于FF 100 μg组。
- 所有治疗组SGRQ总分和ACQ-7评分改善均超过最小临床重要差异(分别为4分和0.5分),但组间无差异。
- 不良事件发生率组间相似(至少1起事件:210 [52%]至258 [63%]),最常见为鼻咽炎、头痛和上呼吸道感染;严重不良事件18 [4%]至25 [6%];3例死亡中1例被认为与研究药物相关(FF/UMEC/VI 100/31.25/25 μg组肺栓塞)。
适用人群与场景
- 年龄≥18岁、ICS/LABA治疗下仍控制不佳的哮喘患者,ACQ-6评分≥1.5。
- 筛选前一年内有因急性哮喘症状就诊或临时调整哮喘治疗的记录。
- 支气管舒张前FEV1占预计值30%至<85%,且筛选时支气管舒张试验阳性(吸入4揿沙丁胺醇或沙丁胺醇后20-60分钟FEV1增加≥12%且≥200 mL)。
诊断标准与关键阈值
- 哮喘控制不佳:ACQ-6评分≥1.5。
- 肺功能纳入标准:支气管舒张前FEV1占预计值30%至<85%。
- 支气管舒张试验阳性:吸入4揿沙丁胺醇或沙丁胺醇后20-60分钟FEV1增加≥12%且≥200 mL。
处置流程与药物剂量
- FF/VI 100/25 μg或200/25 μg,每日一次,经Ellipta干粉吸入器给药。
- FF/UMEC/VI 100/31.25/25 μg、100/62.5/25 μg、200/31.25/25 μg或200/62.5/25 μg,每日一次,经Ellipta干粉吸入器给药。
研究设计与关键结果
- 双盲、随机、平行组、3A期试验(CAPTAIN),从15个国家416家医院和初级保健中心招募,2439例患者随机分配(FF/VI 100/25 μg n=407;200/25 μg n=406;FF/UMEC/VI 100/31.25/25 μg n=405;100/62.5/25 μg n=406;200/31.25/25 μg n=404;200/62.5/25 μg n=408),3例随机分配错误未纳入分析。
- 意向治疗人群:922例(38%)为男性,平均年龄53.2岁(SD 13.1),体重指数29.4(6.6)。
- 主要终点第24周谷FEV1较基线改善:FF/UMEC/VI 100/62.5/25 μg vs FF/VI 100/25 μg为110 mL(95%CI 66-153;p<0.0001);200/62.5/25 μg vs 200/25 μg为92 mL(49-135;p<0.0001)。
- 加用UMEC 31.25 μg:FF/UMEC/VI 100/31.25/25 μg vs FF/VI 100/25 μg为96 mL(52-139;p<0.0001);200/31.25/25 μg vs 200/25 μg为82 mL(39-125;p=0.0002)。
- 关键次要终点中重度急性发作率:FF/UMEC 62.5 μg/VI vs FF/VI(汇总分析)降低未达统计学显著;FF 200 μg组急性发作率低于FF 100 μg组。
- 其他次要终点:第24周SGRQ总分所有汇总治疗组较基线平均改善均超过最小临床重要差异4分,但组间无差异;ACQ-7评分改善均超过最小临床重要差异0.5分;加用UMEC较FF/VI有小的剂量相关改善(汇总分析:FF/UMEC 31.25 μg/VI vs FF/VI为-0.06 [95%CI -0.12至0.01;p=0.094];FF/UMEC 62.5 μg/VI vs FF/VI为-0.09 [-0.16至-0.02;p=0.0084])。
- 高剂量FF对谷FEV1和中重度急性发作率的影响在基线血嗜酸性粒细胞计数和呼出气一氧化氮较高的患者中增加。
- 不良事件:至少1起事件的患者范围为210 [52%]至258 [63%],最常见为鼻咽炎(51 [13%]至63 [15%])、头痛(19 [5%]至36 [9%])和上呼吸道感染(13 [3%]至24 [6%]);严重不良事件范围为18 [4%]至25 [6%];3例死亡,其中1例被认为与研究药物相关(FF/UMEC/VI 100/31.25/25 μg组肺栓塞)。
证据类型、等级与局限
- 证据类型:双盲、随机、平行组、3A期试验。
- 局限:需要进一步的确证性研究来验证2型炎症生物标志物对哮喘治疗结局的区分作用,以扩展这些探索性发现并进一步指导临床实践。
对床旁实践的改变
- 对于ICS/LABA控制不佳的中重度哮喘患者,作者认为单吸入器FF/UMEC/VI是有效治疗选择,具有良好风险获益特征。
- 作者认为高剂量FF主要降低急性发作率,尤其在2型气道炎症生物标志物升高的患者中。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Despite inhaled corticosteroid plus long-acting β2-agonist (ICS/LABA) therapy, 30-50% of patients with moderate or severe asthma remain inadequately controlled. We investigated the safety and efficacy of single-inhaler fluticasone furoate plus umeclidinium plus vilanterol (FF/UMEC/VI) compared with FF/VI.
METHODS: In this double-blind, randomised, parallel-group, phase 3A study (Clinical Study in Asthma Patients Receiving Triple Therapy in a Single Inhaler [CAPTAIN]), participants were recruited from 416 hospitals and primary care centres across 15 countries. Participants were eligible if they were aged 18 years or older, with inadequately controlled asthma (Asthma Control Questionnaire [ACQ]-6 score of ≥1·5) despite ICS/LABA, a documented health-care contact or a documented temporary change in asthma therapy for treatment of acute asthma symptoms in the year before screening, pre-bronchodilator FEV1 between 30% and less than 85% of predicted normal value, and reversibility (defined as an increase in FEV1 of ≥12% and ≥200 mL in the 20-60 min after four inhalations of albuterol or salbutamol) at screening. Participants were randomly assigned (1:1:1:1:1:1), via central based randomisation stratified by pre-study ICS dose at study entry, to once-daily FF/VI (100/25 μg or 200/25 μg) or FF/UMEC/VI (100/31·25/25 μg, 100/62·5/25 μg, 200/31·25/25 μg, or 200/62·5/25 μg) administered via Ellipta dry powder inhaler (Glaxo Operations UK, Hertfordshire, UK). Patients, investigators, and the funder were masked to treatment allocation. Endpoints assessed in the intention-to-treat population were change from baseline in clinic trough FEV1 at week 24 (primary) and annualised moderate and/or severe asthma exacerbation rate (key secondary). Other secondary endpoints were change from baseline in clinic FEV1 at 3 h post-dose, St George's Respiratory Questionnaire (SGRQ) total score, and ACQ-7 total score, all at week 24. Change from baseline in Evaluating Respiratory Symptoms in Asthma total score at weeks 21-24 was also a secondary endpoint but is not reported here. Exploratory analyses of biomarkers of type 2 airway inflammation on treatment response were also done. This study is registered with ClinicalTrials.gov, NCT02924688, and is now complete.
FINDINGS: Between Dec 16, 2016, and Aug 31, 2018, 5185 patients were screened and 2439 were recruited and randomly assigned to FF/VI (100/25 μg n=407; 200/25 μg n=406) or FF/UMEC/VI (100/31·25/25 μg n=405; 100/62·5/25 μg n=406; 200/31·25/25 μg n=404; 200/62·5/25 μg n=408), with three patients randomly assigned in error and not included in analyses. In the intention-to-treat population, 922 (38%) patients were men, the mean age was 53·2 years (SD 13·1) and body-mass index was 29·4 (6·6). Baseline demographics were generally similar across all treatment groups. The least squares mean improvement in FEV1 change from baseline for FF/UMEC/VI 100/62·5/25 μg versus FF/VI 100/25 μg was 110 mL (95% CI 66-153; p<0·0001) and for 200/62·5/25 μg versus 200/25 μg was 92 mL (49-135; p<0·0001). Adding UMEC 31·25 μg to FF/VI produced similar improvements (FF/UMEC/VI 100/31·25/25 μg vs FF/VI 100/25 μg: 96 mL [52-139; p<0·0001]; and 200/31·25/25 μg vs 200/25 μg: 82 mL [39-125; p=0·0002]). These results were supported by the analysis of clinic FEV1 at 3 h post-dose. Non-significant reductions in moderate and/or severe exacerbation rates were observed for FF/UMEC 62·5 μg/VI versus FF/VI (pooled analysis), with rates lower in FF 200 μg-containing versus FF 100 μg-containing treatment groups. All pooled treatment groups demonstrated mean improvements (decreases) in SGRQ total score at week 24 compared with baseline in excess of the minimal clinically important difference of 4 points; however, there were no differences between treatment groups. For mean change from baseline to week 24 in asthma control questionnaire-7 score, improvements (decreases) exceeding the minimal clinically important difference of 0·5 points were observed in all pooled treatment groups. Adding UMEC to FF/VI resulted in small, dose-related improvements compared with FF/VI (pooled analysis: FF/UMEC 31·25 μg/VI versus FF/VI, -0·06 (95% CI -0·12 to 0·01; p=0·094) FF/UMEC 62·5 μg/VI versus FF/VI, -0·09 (-0·16 to -0·02, p=0·0084). By contrast with adding UMEC, the effects of higher dose FF on clinic trough FEV1 and annualised moderate and/or severe exacerbation rate were increased in patients with higher baseline blood eosinophil count and exhaled nitric oxide. Occurrence of adverse events was similar across treatment groups (patients with at least one event ranged from 210 [52%] to 258 [63%]), with the most commonly reported adverse events being nasopharyngitis (51 [13%]-63 [15%]), headache (19 [5%]-36 [9%]), and upper respiratory tract infection (13 [3%]-24 [6%]). The incidence of serious adverse events was similar across all groups (range 18 [4%]-25 [6%)). Three deaths occurred, of which one was considered to be related to study drug (pulmonary embolism in a patient in the FF/UMEC/VI 100/31·25/25 μg group).
INTERPRETATION: In patients with uncontrolled moderate or severe asthma on ICS/LABA, adding UMEC improved lung function but did not lead to a significant reduction in moderate and/or severe exacerbations. For such patients, single-inhaler FF/UMEC/VI is an effective treatment option with a favourable risk-benefit profile. Higher dose FF primarily reduced the rate of exacerbations, particularly in patients with raised biomarkers of type 2 airway inflammation. Further confirmatory studies into the differentiating effect of type 2 inflammatory biomarkers on treatment outcomes in asthma are required to build on these exploratory findings and further guide clinical practice.
参考来源
- Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2020. PMID: 32918892. doi:10.1016/S2213-2600(20)30389-1
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。